Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620811 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
A Phase 3 study, sponsored by Allakos.
- Completed
- Registry status
- Phase 3
- Development phase
- 159
- Enrollment target
NCT04620811 is a Phase 3 study that has completed, run by Allakos. The registered enrollment target is 159 participants.
The verdict
NCT04620811, a Phase 3 study, has completed, sponsored by Allakos.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 159 participants
- Enrollment target
Study Summary
This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.
Interventions
- DRUG lirentelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2020-12-03 |
| Est. Completion | 2023-07-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04620811
The ClinicalTrials.gov registry entry for NCT04620811 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allakos, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lirentelimab is the first listed.
NCT04620811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04620811 about?
NCT04620811 is a clinical study titled "An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)". This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.
What is the current status of trial NCT04620811?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 159 participants. The study started on 2020-12-03. Estimated completion is 2023-07-07.
What interventions are being tested in trial NCT04620811?
The interventions under investigation include: lirentelimab (DRUG).
Who is sponsoring clinical trial NCT04620811?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.